
NSRX
Healthcare · Drug Manufacturers - General · $33.6M market cap
$2.87+0.05 (+1.8%)Nov 13, 3:54 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 25, 2026 | Time not confirmed | -0.53 | 0.00 | +100.0% |
| Dec 3, 2025 | Time not confirmed | -0.14 | -0.14 | 0.0% |
| Sep 3, 2025 | Time not confirmed | — | -0.09 | — |
| Mar 21, 2025 | Time not confirmed | — | -0.09 | — |
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal…